The Latest Breaking News on Pharma

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Mother tells Maya Oppenheim she was forced into having a hysterectomy which meant she ‘car crashed into menopause’ at the age of 45

AMD's budget-friendly B850 and B840 chipset motherboards will seemingly arrive in 2025, limiting AMD's September launch to its higher-end X-series chipsets.

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024?

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter.

Liquidia stock crashed Monday after the FDA delayed the final approval for its drug, Yutrepia, for patients with a pair of lung diseases.

Historic Medicare drug price negotiations are said to lower costs on 10 best-selling drugs, saving Medicare beneficiaries $1.5 billion in out-of-pocket costs in the program's first year.

TG Therapeutics stock is the IBD Stock Of The Day as shares approach two potential entries on newfound profitability and booming sales.

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.